Background: Cilostazol has been reported to prevent atherosclerotic events in the general population. However, data have been limited whether there are beneficial effects of cilostazol use on long-term clinical outcomes after endovascular therapy in hemodialysis (HD) patients with peripheral artery disease (PAD). Methods and results: This study consisted of 595 HD patients undergoing endovascular therapy for a clinical diagnosis of PAD. They were divided into two groups: patients receiving 100 mg cilostazol twice daily in conjunction with standard therapy (n = 249 patients, cilostazol group) and those not administered cilostazol (n = 346 patients, control group). A propensity score analysis was performed to adjust for baseline differences between the two groups. The propensity score-adjusted 10-year eventfree survival rate from major adverse cardiovascular events (MACE) was significantly higher in the cilostazol group than in the control group [58.6% vs. 43.7%, hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.41-0.79; p = 0.0010]. Notably, the adjusted stroke-free rate was significantly higher in the cilostazol group than in the control group (81.6% vs. 74.7%; HR = 0.48; 95% CI, 0.25-0.92, p = 0.028). Even after adjusting for other confounders, treatment with cilostazol was an independent predictor for prevention of MACE and stroke (p = 0.0028 and p = 0.039, respectively). Conclusions: Cilostazol administration improves long-term clinical outcomes including prevention of MACE and stroke after endovascular therapy in HD patients with PAD.
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who are considered to be high-risk individuals for atherosclerotic events, are limited. Therefore, the aim of the present study was to compare long-term clinical outcomes in HD patients who received and those who did not receive cilostazol for clinically diagnosed PAD after revascularization with endovascular therapy (EVT).
Methods

Study population
We performed successful EVT for PAD in 626 HD patients with end-stage renal failure between January 1999 and December 2010. Eligible patients were retrospectively stratified by status of cilostazol treatment: 249 patients receiving 100 mg oral cilostazol twice daily for more than one month before EVT (cilostazol group) and 377 patients who did not receive cilostazol (control group). In advance, 31 patients did not receive cilostazol therapy before EVT, but initiated oral cilostazol during the follow-up period. Predetermined exclusion criteria included an age >80 years and cancer. All patients received successful procedure defined as a final luminal diameter stenosis <30% without angiographically visual arterial dissection. They received oral aspirin for at least 7 days before EVT. The study was conducted in accordance with the guidelines of the ethics committee in our institution, and was approved by the hospital ethics committee. Written informed consent was obtained from each patient.
The primary endpoint was incidence of major adverse cardiovascular events (MACE), defined as a composite of all-cause death, new onset or recurrent stroke including cerebral infarction, cerebral hemorrhage and subarachnoid hemorrhage, and non-fatal myocardial infarction after EVT. The secondary endpoint was major adverse limb events (MALE), a composite of target lesion revascularization (TLR), and major amputation as defined in a previous paper [13] . Data were obtained from hospital charts and through telephone interviews with patients conducted by trained reviewers. Stroke was diagnosed according to clinical signs and/or symptoms followed by confirmation on computed tomography and/or magnetic resonance imaging. Diagnosis of myocardial infarction was based on new ST-segment changes with at least two contiguous electrocardiographic leads, and a more than two-fold elevation of creatine kinase level above the maximum peak in the normal range. To evaluate lower limb peripheral arteries, we performed follow-up examinations, including Doppler sonography, ankle brachial pressure index (ABI) measurement, and/or clinical observations 3 months after EVT and every 6 months thereafter. An angiographical evaluation was performed in cases of an abnormal Doppler waveform >2.4 m/s, worsening clinical symptoms, depressed ABI, worsening critical limb ischemia, and/or the need for limb amputation.
Diabetes was defined as a fasting plasma glucose concentration >126 mg/dl, a randomized plasma glucose concentration >200 mg/dl, glycated hemoglobin A1c levels !6.5% and/or use of anti-hyperglycemic treatment. Hypertension was defined as a systolic blood pressure >160 mmHg, diastolic blood pressure >90 mmHg, and/or use of anti-hypertensive treatment. Dyslipidemia was defined as low-density lipoprotein levels !140 mg/dl, triglyceride levels !150 mg/dl, and/or high-density lipoprotein cholesterol levels <40 mg/dl and/or anti-dyslipidemic medication use. In this study, we defined high-flex membrane as b2 microglobulin clearance !30 ml/min.
Statistical analysis
Statistical analyses were performed using the SPSS 21 software program (SPSS Inc, Chicago, IL, USA). Continuous variables were expressed as mean AE standard deviation. Between-group differences were evaluated with the Student t-test for continuous variables and the chi-square test for categorical variables. Between-group differences in event-free survival were evaluated using the Kaplan-Meier method and compared using a log-rank test. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated with a Cox proportional hazards analysis. To adjust for differences in baseline characteristics between the two groups, a propensity score analysis was performed using a multivariate logistic regression model including all the following baseline covariates: male sex, age, diabetes, hypertension, dyslipidemia, smoking status, body mass index, previous coronary artery disease, previous stroke, critical limb ischemia, TransAtlantic Inter-Society Consensus (TASC) type C or D, femoropopliteal lesion, and stent use. The score was then incorporated into the Cox proportional hazards model as a covariate. Propensity scoreadjusted event-free survival curves were also constructed. Finally, to identify independent predictors of the endpoints, we used Cox multivariable regression models including all covariates with p < 0.05 on the univariate analysis with propensity score. Differences were considered statistically significant at p < 0.05. Table 1 shows the patients' baseline clinical characteristics. There were no significant differences between the two groups. Although coronary artery disease was more frequent in the control group, this did not reach statistical significance. No significant differences in medications other than cilostazol were seen between the two groups. When these medications were evaluated in the multivariate analysis, no significant effects in clinical outcomes were seen (data not shown). Table 2 shows the incidence of the study endpoints during the follow-up period (median 41 months, interquartile range: 21-57 months). In the cilostazol group, both MACE and MALE were less frequent than in the control group. In the Kaplan-Meier analysis, 10-year MACE and MALE event-free rates were significantly higher in the cilostazol group than in the control group (58.3% vs. 43.6%, p = 0.0010, HR = 0.57; 95% CI, 0.41-0.80 and 59.5% vs. 53.5%, p = 0.0056, HR = 0.63; 95% CI, 0.46-0.87, respectively) ( Fig. 1A and  B ). The Kaplan-Meier analysis also showed that the cilostazol group had a higher all-cause stroke-free rate than the control group (82.0% vs. 74.3%, p = 0.017, HR = 0.46; 95% CI, 0.24-0.88) (Fig. 1C) . Interestingly, however, the incidence of hemorrhagic stroke was comparable between the two groups (1.6% vs. 1.3%).
Results
Propensity score analysis
The propensity score-adjusted MACE-free rate was 58.6% in the cilostazol group and 43.7% in the control group (HR = 0.57; 95% CI, 0.41-0.79, p = 0.0010) ( Fig. 2A ). In a Cox multivariable analysis including other significant confounders along with the propensity score, cilostazol treatment (HR 0.58; 95% CI 0.41-0.83; p = 0.0028), ulcer/gangrene prevalence (HR 1.54; 95% CI 1.08-2.20; p = 0.019), and previous stroke (HR 1.79; 95% CI 1.18-2.70; p = 0.0057) independently predicted MACE (Table 3 ). In addition, cilostazol treatment was significantly associated with the prevention of stroke (HR 0.50; 95% CI 0.26-0.96; p = 0.039).
Propensity score-adjusted MALE-free survival was significantly higher in the cilostazol group than in the control group (59.5% vs. 53.5%, p = 0.0058) (Fig. 2B ). After adjustment for other confounders along with the propensity score, cilostazol treatment (HR 0.64, 95% CI 0.46-0.88; p = 0.0068), male (HR 1.44, 95% CI 1.01-2.07, p = 0.044), the prevalence of ulcer/gangrene (HR 1.73, 95% CI 1.23-2.43; p = 0.0016), and stent use (HR 0.63, 95% CI 0.46-0.86; p = 0.0034) were independent predictors of MALE ( Table 3 ). The adjusted stroke-free rate during the 10-year follow-up period was 81.6% in the cilostazol group and 74.7% in the control group (HR = 0.48; 95% CI, 0.25-0.92, p = 0.028) (Fig. 2C) .
As shown in Table 3 , compared to the control group, the cilostazol group had a higher event-free rate for MACE, all-cause death, stroke, MALE, major amputations and TLR.
Discussion
Patients with ESRD have a risk of cardiovascular events that is 20-30 times higher than that of the general population [14] . In addition, the mortality rate of stroke is also high in patients with ESRD [15, 16] . Renal dysfunction has been shown to independently predict poor neurological outcomes, and the frequency of stroke has been shown to be higher in patients with ESRD [17] . The benefit of anticoagulation therapy with warfarin for primary stroke prevention in patients with ESRD is unclear [18] . Although the prevention of cerebrovascular events and mortality is of clinical concern, optimal medical therapies have not been established. The main finding of the present study was that treatment with cilostazol had a beneficial effect in terms of preventing adverse events such as stroke and mortality in HD patients with PAD. Although it has been previously reported that cilostazol treatment prevents stroke in non-HD subjects with PAD, it does not improve the mortality rate in non-HD patients with PAD [11, 19] . From the point of such a view, our findings regarding HD patients were of clinical significance.
The unique effects of cilostazol include both vasodilation and inhibition of neointimal proliferation [10, [20] [21] [22] . We previously reported that, compared to controls, HD patients with PAD who were treated with cilostazol had a higher rate of cumulative patency after EVT [23] . In that study, treatment with cilostazol not only improved the patency of the lower extremities but also prevented stroke and adverse events. One study has reported that HD patients have abnormal platelet function [24, 25] . In addition, HD itself may induce plasma coagulation factors [26] . These mechanisms may cause thrombus formation in HD patients. In that study, ischemic stroke was significantly prevented in the cilostazol group. By contrast, bleeding risk also increases in HD patients [6] . Interestingly, cerebral hemorrhage events were not increased in the cilostazol group in our study. In other words, administration of cilostazol did not affect intracranial hemorrhage, which is consistent with the findings of previous studies [27] . From such points, our findings may have clinical significance for the treatment of HD subjects.
Limitations should be considered when interpreting the data of the study. First, the study had a single-center design with a limited number of enrolled patients. Second, this was not a prospective, randomized, double-blind, controlled study, although a propensity score analysis was conducted. The use of propensity-matched scores may minimize but does not eliminate selection bias. The scores indicate that the decision to use or not use cilostazol was not random. Thus, unseen or unmeasured biases in the interpretation of our results could not be ruled out. Third, the effects of other specific drugs and/or drug combinations may have affected the results. Fourth, recent studies have shown that a good clinical outcome is achieved in patients with residual renal function even if they are treated with HD [28, 29] . In this study, we did not routinely evaluate residual renal function. Finally, exercise tolerance was not assessed in the present study. One report has suggested that exercise has a beneficial effect on endothelial function in patients with PAD [30] . This effect may prevent atherothrombotic events.
In HD patients with a clinical diagnosis of PAD, treatment with cilostazol improved long-term clinical outcomes including the prevention of both stroke and all-cause mortality. We believe that administration of cilostazol may have a substantial potential for improving outcomes due to its effect in preventing atherosclerotic events in HD patients. A large, prospective, randomized multicenter study is needed to confirm our findings. 
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